The weekly litigation news digest is live. Subscribe now

IP Verse

Medicaments For Increasing Endogenous Erythropoietine (Epo) - EP2289531

The patent EP2289531 was granted to Fibrogen on Jul 4, 2018. The application was filed on Dec 6, 2002 under application number EP10181768A. The patent is currently recorded with a legal status of "Revoked".

EP2289531

FIBROGEN
Application Number
EP10181768A
Filing Date
Dec 6, 2002
Status
Revoked
May 16, 2025
Publication Date
Jul 4, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GLAXOSMITHKLINEFeb 19, 2020GODDARDINTERVENTION WITHDRAWN
AKEBIA THERAPEUTICSApr 3, 2019JONES DAYADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0650960
DESCRIPTIONEP0650961
DESCRIPTIONUS4558006
DESCRIPTIONUS4667016
DESCRIPTIONUS5474796
DESCRIPTIONUS5605662
DESCRIPTIONUS5607954
DESCRIPTIONUS5610172
DESCRIPTIONUS5620995
DESCRIPTIONUS5620996
DESCRIPTIONUS5658933
DESCRIPTIONUS5719164
DESCRIPTIONUS5726305
DESCRIPTIONUS5916898
DESCRIPTIONUS6020350
DESCRIPTIONUS6093730
DESCRIPTIONUS6200974
DESCRIPTIONWO0050390
DESCRIPTIONWO9525116
DESCRIPTIONWO9535505
DESCRIPTIONWO9921860
EXAMINATIONDE10010423
EXAMINATIONEP0765871
EXAMINATIONEP0911340
EXAMINATIONEP1463823
EXAMINATIONWO9741103
OTHEREP1463823
OTHEREP1633333
SEARCHDE10010430

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents